XML 72 R52.htm IDEA: XBRL DOCUMENT
v3.20.4

License and Collaboration Agreements - Schedule of Payments Allocated to Performance Obligations (Details) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2020 USD ($)
Allocation of transaction price |
Upfront cash consideration | $ 175,000
Payment for access rights related to the Company's research and development pipeline | 100,000
Premium from Stock Purchase Agreement | 90,600
Total transaction price allocated to revenue | 365,600
Allocation to performance obligations |
Zimberelimab license | 55,096
Etrumadenant option | 126,960
Domvanalimab option | 36,728
Access rights related to the Company's research and development pipeline | 137,113
Development and commercialization services for zimberelimab | 9,703
Total | $ 365,600

X
- Definition Access rights related to the company's research and development pipeline. + References No definition available. + Details
Name: | rcus_AccessRightsRelatedToCompanySResearchAndDevelopmentPipeline
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocation of transaction price + References No definition available. + Details
Name: | rcus_AllocationOfTransactionPrice
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocation of transaction price. + References No definition available. + Details
Name: | rcus_AllocationOfTransactionPriceAbstract
Namespace Prefix: | rcus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Allocation to performance obligations. + References No definition available. + Details
Name: | rcus_AllocationToPerformanceObligations
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and commercialization services for zimberelimab. + References No definition available. + Details
Name: | rcus_DevelopmentAndCommercializationServicesForZimberelimab
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Domvanalimab option. + References No definition available. + Details
Name: | rcus_DomvanalimabOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Etrumadenant option. + References No definition available. + Details
Name: | rcus_EtrumadenantOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment for access rights related to the Company's research. + References No definition available. + Details
Name: | rcus_PaymentForAccessRightsRelatedToTheCompanySResearch
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Premium from stock purchase agreement. + References No definition available. + Details
Name: | rcus_PremiumFromStockPurchaseAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | rcus_UpfrontCashPayment
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Zimberelimab license. + References No definition available. + Details
Name: | rcus_ZimberelimabLicense
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuePerformanceObligationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration